» Articles » PMID: 33130384

Osteosarcoma: A Comprehensive Review of Management and Treatment Strategies

Overview
Specialty Pathology
Date 2020 Nov 1
PMID 33130384
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma, a bone cancer usually seen in children and young adults, is generally a high-grade malignancy presented by extreme metastases to the lungs. Osteosarcoma has a tendency for appearing in bones with rapid growth rate. The etiology of osteosarcoma is multifaceted and poorly understood. A molecular consideration of this disease will lead to a directed tumor treatment. The present treatment for osteosarcoma comprises of an arrangement of systemic chemotherapy and wide surgical resection. Survival rate is increased by the progress of destructive systemic chemotherapies. So, the development of new treatment approaches for metastatic osteosarcoma is essential. Immunomodulation has been used in clinical settings. Through targeting surface antigens expressed on tumor cells, particular antibodies and exploitation of cellular immunotherapy against sarcomas have been confirmed to be effective as cancer therapeutics. In this article, we have reviewed epidemiology, etiology, pathogenesis, diagnosis, and treatment of osteosarcoma and we have focused on different methods of immunotherapy including vaccines, cell-based immunotherapy, cytokines, and monoclonal antibodies.

Citing Articles

Exploring Narrative and Coping Strategies of Osteosarcoma Survivors in China: A Qualitative Study.

Peng Z, Hung S, Fung K Cancer Rep (Hoboken). 2025; 8(3):e70170.

PMID: 40034064 PMC: 11876858. DOI: 10.1002/cnr2.70170.


Unveiling the effects of GSK126 on osteosarcoma cells implications for apoptosis, autophagy, and cellular migration.

Xiong X, Liu Y, Du Y, Lai X, Si C, Miao H Discov Oncol. 2025; 16(1):245.

PMID: 40014170 PMC: 11868014. DOI: 10.1007/s12672-025-02010-7.


Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics.

Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J Front Immunol. 2025; 16:1539396.

PMID: 39991153 PMC: 11842356. DOI: 10.3389/fimmu.2025.1539396.


Daidzin improves the cisplatin chemosensitivity for osteosarcoma via binding to β-catenin protein and suppressing the wnt pathway.

Wang P, Lu H, Zhang C, Wang R, Chen X, Qiao L Sci Rep. 2025; 15(1):5484.

PMID: 39953179 PMC: 11829052. DOI: 10.1038/s41598-025-89766-8.


Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment.

Benjamin A, Nayak S Discov Nano. 2025; 20(1):18.

PMID: 39883285 PMC: 11782756. DOI: 10.1186/s11671-024-04163-w.